Ionis Pharmaceuticals, a California company, conducted two late-stage clinical trials on an experimental therapy for hereditary angioedema. The results showed significant benefits for patients, including those already on existing medications. In one trial, patients given injections of the therapy had a significant reduction in swelling attacks compared to those given a placebo. The second trial showed a further reduction in swelling attacks after up to a year of treatment, regardless of dosing frequency. Patients who switched to the new therapy from existing treatments also experienced a reduction in swelling attacks. These findings suggest promising results for the new therapy in treating hereditary angioedema.
Source link
Ionis drug prevents swelling attacks due to hereditary angioedema
